Phase 1 N=20 An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants
Sepsis
Primary: PK of Daptomycin — 262.4 mg*h/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Lapatinib in Combination With Vinorelbine
Cancer
Primary: Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 — 0; 4; 12; 0 participants
N/A N=5 Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery
Intrauterine Growth Retardation
Primary: Survival — 100; 100 percentage of AGA babies who survived
Phase 3 N=211 A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With Adverse Events Leading to Discontinuation — 29 participant
Phase 3 N=870 Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
Osteoporosis
Primary: Total Hip BMD Percent Change From Baseline at Month 12 — 0.5; 2.0 Percent Change From Baseline — p=<0.0001
Phase 4 N=110 The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
Coronary Artery Disease
Primary: Inhibition of Platelet Aggregation (IPA) in Prasugrel-treated and Clopidogrel-treated Smokers and Non-smokers Following 9 Days of Maintenance Therapy. — 70.3; 65.6…
Phase 2 N=260 Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
Respiratory Syncytial Virus Infections · Chronic Lung Disease and <= 24 Months of Age or · Premature With Gestational Age <=35 Weeks and <=6 Months of Age
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 19; 7; 11 participants
Phase 2 N=242 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in Observed Total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Score at Week 4 of Treatment Cycle 1 — 40.4; 41.5; 39.6; -10.3 Scores…
Phase 2 N=32 Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Malignant Ascites
Primary: The Proportion of Patients Who Achieved at Least a 4-fold Increase of Puncture/Paracentesis-free Interval Following Catumaxomab Relative to Their Pre-treatment Interval…
Phase 2 N=50 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
Substance Abuse
Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples
N/A N=501 Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Macular Degeneration
Primary: Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection — 1.34; 2.19; 0.48; 2.50 percent per injection
N/A N=42 Evaluating Transcutaneous Electrical Nerve Stimulation for Postoperative Pain After Video-Assisted Thoracotomy Surgery
Postoperative Pain
Primary: Mean Pain Score — 4.55; 3.85; 4.30; 3.80 units on a scale
Phase 4 N=611 Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Body Weight — -1.05; -0.56 kg — p=0.132
Phase 3 N=207 Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
Epilepsy; Paediatric Partial Onset Seizures
Primary: Percentage of Participants With a Decrease From Baseline in 28-day Seizure Frequency of =50%(Responder) in the Maintenance Period(LOCF) — 31; 50 Percentage of Participants
Phase 3 N=36 Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Diabetes Mellitus · Postprandial Lipemia
Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L